E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Spinal Muscular Atrophy |
Atrofia Muscular Espinal |
|
E.1.1.1 | Medical condition in easily understood language |
Spinal Muscular Atrophy |
Atrofia Muscular Espinal |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041582 |
E.1.2 | Term | Spinal muscular atrophy |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to characterize the safety and tolerability of OAV101 intrathecal (IT) over a 52-week period in patients with SMA aged 2 to 12 years who have discontinued treatment with nusinersen (Spinraza®) or risdiplam (Evrysdi®). |
El objetivo principal de este estudio es caracterizar la seguridad y la tolerabilidad de OAV101 intratecal (IT) durante un periodo de 52 semanas en pacientes de 2 a 12 años de edad con AME que hayan discontinuado el tratamiento con nusinersen (Spinraza®) o risdiplam (Evrysdi®). |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of this study is to assess the efficacy of OAV101 IT on motor function and caregiver impact over a 52-week period in patients with SMA aged 2 to 12 years who have discontinued treatment with nusinersen (Spinraza®) or risdiplam (Evrysdi®). |
El objetivo secundario de este estudio es evaluar la eficacia de OAV101 IT en la función motora y el impacto en el cuidador durante un periodo de 52 semanas en pacientes de 2 a 12 años de edad con AME que hayan discontinuado el tratamiento con nusinersen (Spinraza®) o risdiplam (Evrysdi®). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
● Written informed consent ● SMA diagnosis based on gene mutation analysis with bi-allelic SMN1 mutations and any copy of SMN2 gene ● Aged 2 to 12 years at time of Screening Visit 1 ● Have had at least four loading doses of nusinersen (Spinraza®) or at least 3 months of treatment with risdiplam (Evrysdi®) at Screening ● Must be able to sit independently but must never have taken steps independently ● Diagnosed through newborn or neonatal screening or patients clinically diagnosed must have age of clinical symptom onset < 18 months ● Meets age-appropriate institutional criteria for use of anesthesia/sedation ● Female participants who are sexually active or have reached menarche must have a negative pregnancy test at Screening. Those females who are sexually active must also agree to use highly effective methods of contraception. |
- Consentimiento informado por escrito. - Diagnóstico de AME con mutaciones bialélicas en el gen SMN1 y cualquier copia del gen SMN2 basado en un análisis de mutación genética. - De 2 a 12 años de edad en el momento de la visita de selección 1. - Haber recibido al menos cuatro dosis de carga de nusinersen (Spinraza®) o bien tratamiento con risdiplam (Evrysdi®) durante al menos 3 meses en la selección. - Poder sentarse solos, pero nunca haber dado pasos de forma independiente. - Los pacientes diagnosticados en pruebas neonatales o los pacientes con un diagnóstico clínico deben tener <18 meses de edad al inicio de los síntomas clínicos. - Cumplir los criterios de edad establecidos por el centro para el uso de anestesia/sedación. - Las participantes que sean sexualmente activas o hayan llegado a la menarquia deben presentar un resultado negativo en una prueba de embarazo en la selección. Las mujeres que sean sexualmente activas también deberán aceptar utilizar métodos anticonceptivos altamente eficaces. |
|
E.4 | Principal exclusion criteria |
● Excluding SMA, any medical condition considered clinically significant ● Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis ● Anti Adeno Associated Virus Serotype 9 (AAV9) antibody titer using an immunoassay is reported as elevated (reference to >1:50 or a validated result consistent with being elevated) ● Clinically significant abnormalities in test results during screening period and/or at Baseline ● Platelet count less than the lower limit of normal (LLN), or platelet transfusion within 1 month at Screening Visit 1 ● Abnormal coagulation panel results at Screening ● Hepatic dysfunction (i.e. alanine aminotransferase (ALT), total bilirubin (TBL), gamma-glutamyl transferase (GGT) or glutamate dehydrogenase (GLDH) > upper limit of normal (ULN) at Screening (with the exception of isolated AST elevation: in the absence of other liver laboratory abnormalities, isolated elevated AST is not considered exclusionary) ● Contraindications for lumbar puncture procedure ● At Baseline (Day-1), participants are excluded if they received: ●nusinersen (Spinraza®) within 4 months at Baseline ● risdiplam (Evrysdi®) within 15 days at Baseline ● Vaccinations 2 weeks prior to administration of OAV101 ● Hospitalization for a pulmonary event, or for nutritional support within 2 months prior to Screening or inpatient major surgery planned. ● Presence of the following: ● An active infectious process requiring systemic antiviral or antimicrobial therapy at any time between Screening Visit 1 and OAV101 administration, or ● An active but untreated viral or bacterial infectious process at any time between Screening Visit 1 and administration of OAV101, or ● Any febrile illness within two weeks prior to Screening Visit 1 and up to administration of OAV101 ● Requiring invasive ventilation, awake noninvasive ventilation for > 6 hours during a 24-hour period, noninvasive ventilation for >12 hours during a 24-hour period or requiring tracheostomy, at Screening and up to OAV101 administration ● Concomitant use of any of the following medication categories within 90 days prior to administration of OAV101 ● Ongoing immunosuppressive therapy (e.g., corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab), plasmapheresis, immunomodulators (e.g., adalimumab) ● History of hypersensitivity to any of the study treatments or its excipients or drugs of similar chemical classes |
- Cualquier enfermedad considerada de interés clínico excluyendo la AME. - Resultado positivo en una prueba del virus de la inmunodeficiencia humana (VIH), de hepatitis B o de hepatitis C. - El título de anticuerpos anti-virus adenoasociado de serotipo 9 (AAV9) usando un inmunoensayo se informa como elevado (referencia a >1:50 o un resultado validado consistente con estar elevado) - Anomalías de interés clínico en los resultados de las pruebas durante el periodo de la selección o en la basal. - Recuento de plaquetas por debajo del límite inferior de normalidad (LIN) o transfusión de plaquetas durante el mes anterior a la visita de selección 1. - Resultados anormales en las pruebas de coagulación en la selección. - Disfunción hepática (es decir, alanina aminotransferasa (ALT), bilirrubina total (BT), gamma glutamiltransferasa (GGT) o glutamato deshidrogenasa (GLDH) >límite superior de normalidad (LSN) en la selección (con la excepción de elevación aislada de AST: si no presentan otras anomalías analíticas hepáticas, la AST elevada aislada no se considera excluyente). - Contraindicaciones para el procedimiento de punción lumbar. - En la basal (día -1), los participantes están excluidos si han recibido: -- Nusinersen (Spinraza®) durante los 4 meses anteriores a la basal. -- Risdiplam (Evrysdi®) durante los 15 días anteriores a la basal. - Vacunas 2 semanas antes de la administración de OAV101. - Hospitalización por un acontecimiento pulmonar o para apoyo nutricional durante los 2 meses anteriores a la selección o cirugía mayor prevista con ingreso hospitalario. - Presencia de: -- Un proceso infeccioso activo que requiera tratamiento antiviral o antimicrobiano sistémico en cualquier momento entre la visita de selección 1 y la administración de OAV101, o -- un proceso infeccioso vírico o bacteriano activo y sin tratar en cualquier momento entre la visita de selección 1 y la administración de OAV101, o -- cualquier enfermedad febril durante las dos semanas anteriores a la visita de selección 1 y hasta la administración de OAV101. - En la selección y hasta la administración de OAV10, requerir ventilación invasiva o ventilación no invasiva durante la vigilia durante >6 horas en un periodo de 24 horas, ventilación no invasiva durante >12 horas en un periodo de 24 horas o traqueotomía. - Uso concomitante de cualquiera de las siguientes categorías de medicamentos durante los 90 días anteriores a la administración de OAV101: -- Tratamiento en curso con inmunosupresores (p. ej., corticosteroides, ciclosporina, tacrolimus, metotrexato, ciclofosfamida, inmunoglobulina intravenosa o rituximab), plasmaféresis o inmunomoduladores (p. ej., adalimumab). - Antecedentes de hipersensibilidad a alguno de los tratamientos del estudio o sus excipientes o a fármacos de clases químicas similares. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints for the primary objectives are: the number and percentage of participants reporting adverse events (AEs), related AEs, serious AEs and adverse events of special interest (AESIs) over a 52-week period. |
Las variables principales para los objetivos principales son: el número y el porcentaje de participantes que informaron eventos adversos (EA), EA relacionados, EA graves y eventos adversos de especial interés (AESI) durante un período de 52 semanas. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints for the secondary objective questions of interest are: ● What is the change from baseline to Week 52 visit in the Hammersmith Functional Motor Scale Expanded (HFMSE) total score? ● What is the change from baseline to Week 52 visit in the Revised Upper Limb Module (RULM) total score? ● What is the change from baseline to Week 52 visit in Assessment of Caregiver Experience in Neuromuscular Disease (ACEND) instrument score? |
Las variables secundarias de las cuestiones de interés del objetivo secundario son: - ¿Cuál es el cambio desde la basal hasta la visita de la semana 52 en la puntuación total obtenida en la evaluación Hammersmith Functional Motor Scale Expanded (HFMSE)? - ¿Cuál es el cambio desde la basal hasta la visita de la semana 52 en la puntuación total obtenida en la evaluación Revised Upper Limb Module (RULM)? - ¿Cuál es el cambio desde la basal hasta la visita de la semana 52 en la puntuación obtenida en la evaluación Assessment of Caregiver Experience in Neuromuscular Disease (ACEND)? |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tolerabilidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Japan |
United States |
France |
Netherlands |
Spain |
Germany |
Italy |
Belgium |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study completion is defined as when the last participant finishes their Study Completion visit and any repeat assessments associated with this visit have been documented and followed-up appropriately by the Investigator or, in the event of an early study termination decision, the date of that decision. |
La finalización del estudio se define cuando el último participante finaliza su visita de finalización del estudio y cualquier evaluación repetida asociada a esa visita, ha sido documentada y seguida adecuadamente por el investigador o, en el caso de una decisión de finalización anticipada del estudio, la fecha de esa decisión. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 21 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 10 |